Daniel Wynn is a Neurology physician affiliated with Consultants in Neurology. OpenAlex indexes 65 publications with 5,718 citations (h-index 32); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1535 Lake Cook Rd
Suite 601
Northbrook, IL 600621447
Telephone
847-509-0270Provider last certified this registry record 5 Feb 2025.
Clinical trials
- Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
Sponsor: Acorda Therapeutics
- Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Sponsor: PDL BioPharma, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
82 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- EMD Serono, Inc.Program year202528 payments$22,579openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20256 payments
- Vanda Pharmaceuticals Inc.Program year202528 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
66.6%SSRI9.7%Escitalopram Oxalate52%Sertraline Hcl21%Paroxetine Hcl12%Trazodone Hcl11%Fluoxetine Hcl6%Part D<11 patientsOther antiepileptics6.2%Topiramate57%Levetiracetam26%Lacosamide17%Part D<11 patients+ 22 more classes in this area
Cancer & immunology
18.7%Pyrimidine Synthesis Inhibitor6.3%Teriflunomide89%Aubagio11%Part D<11 patientsOther immunostimulants6.1%Copaxone38%Glatiramer Acetate33%Glatopa29%Part D<11 patients+ 4 more classes in this area
Musculoskeletal
11.9%gamma-Aminobutyric Acid-ergic Agonist7.7%Baclofen100%Part D≥46 patientsCentral alpha-2 Adrenergic Agonist3%Tizanidine Hcl100%Part D≥21 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”